Iksuda Therapeutics and Femtogenix sign license agreement

Agreement gives Iksuda access to Femtogenix’s therapeutic payloads to advance lead ADC for difficult-to-treat solid tumours

Newcastle, UK, 5th March 2019: Iksuda Therapeutics (Iksuda), the next-generation Antibody Drug Conjugate (ADC) company, today announced it has signed a licensing agreement with Femtogenix Limited (FGX), the next-generation ADC payload company. As part of this agreement, Iksuda will use FGX’s sequence-selective DNA-interactive payload molecules to progress its lead ADC towards the clinic, with the aim of targeting difficult-to-treat solid tumours.

By harnessing FGX’s highly potent and broad-acting DNA mono-alkylating payloads in combination with its own PermaLink® conjugation platform, Iksuda aims to significantly improve the therapeutic index of its ADCs and further advance the current standard of care for solid tumour types, which can be resistant to treatment. The agreement marks another key step in the build-out of Iksuda’s ADC technology-suite and drug pipeline, from which it aims to progress multiple candidates towards first clinical studies in 2020.

Dr Dave Simpson, Chief Executive Officer, Iksuda, said: 

“This agreement is an exciting progression of our ADC pipeline as it maximises potential for the greatest anti-cancer impact and enhanced therapeutic index, further underpinning our ambition to advance multiple ADCs to the clinic and treat the broadest patient population possible.”

Dr Chris Keightley, Chief Executive Officer, Femtogenix, said:

“We are pleased to be working with Iksuda to further validate the clinical potential of our payloads, which should provide improved efficacy and safety in comparison to those currently in the clinic. We have developed a wide range of easily conjugated payloads with novel mechanisms of action and potency levels, and these are available for licensing. In particular, we are developing payloads that can recognise and bind to transcription factor recognition site profiles within the genome. Such profiles are characteristic of specific tumour types, and this allows FGX to develop payloads with reduced toxicity and enhanced target specificity.”

For more information please contact:

Iksuda Therapeutics
Dave Simpson, Chief Executive Officer
Tel: +44 (0) 191 6031680
Email: [email protected]
Website: www.iksuda.com

Chris Keightley, Chief Executive Officer
Tel: +44 (0) 203 8580153
Email: [email protected]
Website: www.femtogenix.com

Zyme Communications (Trade and Regional Media)
Lorna Cudden
Tel: +44 (0) 7811 996 942
Email: [email protected]

FTI Consulting (Financial Media and IR)
Simon Conway / Rob Winder
Tel: +44 (0) 020 3727 1000